Targets › CD93
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.
Cell surface receptor that plays a role in various physiological processes including inflammation, phagocytosis, and cell adhesion. Plays a role in phagocytosis and enhances the uptake of apoptotic cells and immune complexes by acting as a receptor for defense collagens including surfactant protein A/SFTPA1, C1q, and mannose-binding lectin (MBL2). (UniProt, Q9NPY3)
Open in Phaseline: the race on CD93, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| DynamiCure Biotechnology | DCSZ11 Monoclonal antibody targeting CD93 | CD93 | Phase 1 | Advanced or Metastatic Solid Tumors | Dec 2026 |
Advanced or Metastatic Solid Tumors (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.